Rome, Italy
2 march 2017
Scroll down to read the story

welcome

by
David Bates

ms patien
has changed
during last
20 years

disease
management

how to guide
treatment decisions

Today´s MS Patient

A complete transformation of the MS landscape


Milder disease & treated earliers
Positive impact on cognitive impairment

by
Celia Oreja
by
Jiwon Oh

our
understanding
of MS
has evolved
over time

population is changing

ms patients
are treated
earlier

diagnostic
criteria
has evolved

more
advanced guidelines

there are
a lot of
new
treatments

MRI can detect
subclinical
disease activity

we need to monitore

challenges

cost

identify those patients
with low response

lack of
reproducibility

high technical

expertise

who have decrease

new cortical lesions

Role of DMDs in delaying disability progression

by
Claudio Gasperini

reduction
in relapses
over long term

progression
is limited in
moderm population

early treatment is
essential
treat early
treat the patients
as early as possible

mantain
patient
quality
of life

is the key goal

delay disability
over long term

long-term rebif® treatment had favorable
effects on EDSS outcomes

therapeutic mechanisms impact the immune system

by
Sven Schippling

safety
considerations
with MS therapies
are linked to the
very mechanisms
that mediate
their beneficial
effects

REBIF® has a
well-characterized
safety
profile

Monitoring
requirements
vary between
treatments

Patient
and clinical
trial
experience

efficacy against potential side effects

safety benefit

efficacy risk

the risk balance

balancing safety & efficacy
guiding treatment decisions

by
Raed Alroughani

Pregnancy is key
consideration for
patients when
determine the
appropiate
treatment therapies

Breastfeeding
is an
important
consideration

appropriate treatment
switching

by
Liliana Patrucco

why

how

consider balance
between
efficacy and safety

it´s important
to consider
the prognostic
of the disease

depends on
the risk
of the patient
non
responders patient

we need some study

me need some data

what is treatment failure?

treatment de-scalation

- scenarios -

there is a lack of consense - guidelines

look at the evidence


patients
who are
considenring
pregnancy

safety
and
TOLERABILITY
issues


benefits
vs
risk

lack
of
efficacy

there is a safety concern

REBIF® KEEPS MOVING FORWARD

efficacy
proven

early impact

Beneficial effect
maintained with
long term treatment

patients should
be encourage
undertake lifestyle
changes to help
manage cognitive
symptoms

significantly
reduces new gd

+

lesions in early
disease

REBIF®
is experience that
keeps going

8/10
patient did not
need walking aid

reduce
MRI burden
of disease

reduced the risk of
disability progression
in RRMS versus
delayed treatment

making decisions
based on the need to
balance
safety and efficacy

Panel discussion

there is
always a way
to make your
experience
better

there is
a risk
of progression
in strong therapy

it is a
pragmatic
approach

the concept
reconstitution
of the immune
system

tolerability
to drugs

how to reach
the goal?

consider the activity of the patient